Treatment and Outcome of AIDS-related Lymphoma

非霍奇金淋巴瘤（NHL）是获得性免疫缺陷（AIDS）患者中死亡率不断上升的原因，这是由于使用高效抗逆转录病毒治疗（HAART）降低了机会性感染（OI）率。 虽然艾滋病相关的非霍奇金淋巴瘤的预后一直很差，在过去，HAART可能会改善结果。具体目标：1）我们将使用快速病例确定方法从基于人群的癌症登记处确定NHL患者伴或不伴AIDS。2)我们将描述艾滋病-非霍奇金淋巴瘤患者的艾滋病毒特异性患者和治疗特点，并区分哪些因素影响预后。3)我们将描述非霍奇金淋巴瘤伴或不伴艾滋病患者的肿瘤特征和癌症治疗，并区分哪些肿瘤学特征影响预后。 4)我们将确定HAART的使用如何影响国际预后指数（IPI），并形成一个原始的预后模型。研究设计：使用快速病例确认，我们将联系橙子、圣地亚哥和帝国县癌症登记处在两年期间报告的所有艾滋病-NHL病例，以及在同一两年期间报告的年龄、性别和种族/民族匹配的非艾滋病NHL病例样本。 我们将对NHL患者进行访谈和图表审查，以收集影响预后的生物学因素的信息，例如NHL部位，分期和病理分级以及患者特定特征，例如种族/民族，体能状态和医疗保健服务。 我们将收集有关HIV特异性特征的数据，包括CD 4细胞计数、HIV病毒载量、HIV风险因素以及NHL合并艾滋病患者使用HAART的情况。 我们将比较接受HAART和未接受HAART的NHL患者的生存率、合并症/OI的发生率和生活质量（QOL）。 最后，我们将确定HAART的使用如何影响IPI，并开发一个预后模型，将HIV相关因素，肿瘤特征，HAART和化疗结合起来。

Non-Hodgkin's lymphoma (NHL) is an increasing cause of death among people with acquired immunodeficiency (AIDS) due to declining rates of opportunistic infection (OI) with the use of highly active antiretroviral therapy (HAART). While the prognosis of AIDS- related NHL has been poor in the past, HAART may improve outcomes. Specific Aims: 1) We will identify NHL patients with and without AIDS from the population-based cancer registry using a rapid case ascertainment method. 2) We will describe HIV-specific patient and treatment characteristics of AIDS-NHL patients and distinguish which factors influence prognosis. 3) We will describe tumor characteristics and cancer treatment in NHL patients with and without AIDS and distinguish which oncologic features influence prognosis. 4) We will determine how the use of HAART influences the International Prognostic Index (IPI) and form an original prognostic model. Research Design: Using rapid case ascertainment, we will contact all AIDS-NHL cases reported in a two-year period to the cancer registry for Orange, San Diego, and Imperial Counties and a sample of non- AIDS NHL cases matched on age, sex and race/ethnicity reported during the same two-year period. We will perform interviews and chart reviews on NHL patients to collect information on biologic factors that influence prognosis such as such as NHL site, stage, and pathologic grade as well as patient-specific features such as race/ethnicity, performance status, and health care access. We will gather data on HIV-specific features including CD4 cell count, HIV viral load, HIV risk factors, and use of HAART for NHL patients with AIDS. We will compare survival, development of co-morbidities/OI, and quality of life (QOL) between NHL patients with and without AIDS over a three-year follow-up period between AIDS patients who receive HAART and those who do not. Lastly, we will determine how the use of HAART influences the IPI and develop a prognostic model that incorporates HIV-related factors, tumor characteristics, HAART, and chemotherapy.